Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid

OBJECTIVE: Oligomeric forms of amyloid β protein (oAβ) are believed to be principally responsible for neurotoxicity in Alzheimer disease (AD), but it is not known whether anti‐Aβ antibodies are capable of lowering oAβ levels in humans. METHODS: We developed an ultrasensitive immunoassay and used it...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Neurol
Autors principals: Yang, Ting, Dang, Yifan, Ostaszewski, Beth, Mengel, David, Steffen, Verena, Rabe, Christina, Bittner, Tobias, Walsh, Dominic M., Selkoe, Dennis J.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6771589/
https://ncbi.nlm.nih.gov/pubmed/31168802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ana.25513
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars